CPRX -- Hoffnung für Kokainsüchtige - 500 Beiträge pro Seite
eröffnet am 10.05.09 17:37:50 von
neuester Beitrag 28.02.10 13:58:13 von
neuester Beitrag 28.02.10 13:58:13 von
Beiträge: 18
ID: 1.150.279
ID: 1.150.279
Aufrufe heute: 0
Gesamt: 3.008
Gesamt: 3.008
Aktive User: 0
ISIN: US14888U1016 · WKN: A0LCUL · Symbol: CPRX
15,905
USD
-2,24 %
-0,365 USD
Letzter Kurs 18:36:44 Nasdaq
Neuigkeiten
13:03 Uhr · globenewswire |
27.03.24 · globenewswire |
16.08.23 · globenewswire |
14.08.23 · globenewswire |
09.08.23 · globenewswire |
Werte aus der Branche Pharmaindustrie
Wertpapier | Kurs | Perf. % |
---|---|---|
1,5200 | +76,95 | |
0,7500 | +50,00 | |
5,8000 | +43,21 | |
12,950 | +32,55 | |
0,7630 | +26,53 |
Wertpapier | Kurs | Perf. % |
---|---|---|
3,8500 | -16,12 | |
7,5000 | -16,67 | |
1,9000 | -18,80 | |
1,4600 | -27,00 | |
3,6400 | -38,62 |
Ich hab vorgestern meine 2000€ von meinem Kollegen wieder bekommen die ich ihm geliehen hatte , und was macht man am besten mit dem geld natürlich anlegen
Da es kein großer Betrag ist wollte ich auf Risiko gehen und da kam mir CPRX in den sinn die ich schon lange verfolge .
Warum ausgerechnet CPRX ? ganz einfach
1. Produkt (CPP-109) ist äußerst Interessant
2. US-Phase II Daten noch im 2Q 2009
3. Pilot Phase II Studie in Mexiko waren positiv (deshalb bin ich für US-Daten Optimistisch)
4. Insider und vor allem Mitglieder von CPRX haben ständig Aktien von CPRX gekauft
5. Die Aktie ist kaum bekannt ( was für mich immer wichtig ist)
Hier kann ich euch auch beweisen das US-BioAktien wesentlich leichter zu Pushen sind achtet auf mein Kauf in Frankfurt und kurze Zeit später dann der Kurssprung in USA
Sieht aus als würde die Party nächste Woche hier weitergehen
Catalyst Pharma ( CPRX )
Marktkap : 27 Mio US$
Cash : 11,8 Mio US$
Kurs 1,78 $
Shares Out : 14,1 Mio Aktien
Insider
http://finance.yahoo.com/q/it?s=CPRX
Homepage
http://www.catalystpharma.com/about.htm
Catalyst focuses on drug to treat addicts
Catalyst Pharmaceuticals in Coral Gables is developing a drug
that could be a major help to addicts who want to quit.
BY JOHN DORSCHNER
jdorschner@MiamiHerald.com
Catalyst Pharmaceutical Partners in Coral Gables has a single drug, but it has huge potential: It suppresses dopamine levels in the brain, which could be a major factor in battling cocaine and methamphetamine addiction — and perhaps treat nicotine, alcohol, obesity and gambling problems as well.
Catalyst is a young Coral Gables drug company with a veteran industry chief executive who is betting everything on vigabatrin, an interesting drug with a long history and a problematic side effect.
"Everybody is really excited and pumped," says Chief Executive Patrick J. McEnany of the small team he has assembled.
"Drug development is a risky business. There is no doubt about it," says McEnany.
But much of the toughest work has already been done, by a federal scientist who has been studying the drug for two decades at taxpayer expense. If the drug succeeds, Catalyst could get hundreds of millions in annual revenue, but the firm will have to pay the government no more than $500,000 a year.
What's more, the Food and Drug Administration has put vigabatrin on a fast track for regulatory approval because it provides an unmet medical need for a life-threatening illness.
Vigabatrin was developed in the 1970s by an American company for the treatment of epilepsy. Under the brand name Sabril, it is now sold by a Belgium firm in more than 60 countries, but not the United States.
Da es kein großer Betrag ist wollte ich auf Risiko gehen und da kam mir CPRX in den sinn die ich schon lange verfolge .
Warum ausgerechnet CPRX ? ganz einfach
1. Produkt (CPP-109) ist äußerst Interessant
2. US-Phase II Daten noch im 2Q 2009
3. Pilot Phase II Studie in Mexiko waren positiv (deshalb bin ich für US-Daten Optimistisch)
4. Insider und vor allem Mitglieder von CPRX haben ständig Aktien von CPRX gekauft
5. Die Aktie ist kaum bekannt ( was für mich immer wichtig ist)
Hier kann ich euch auch beweisen das US-BioAktien wesentlich leichter zu Pushen sind achtet auf mein Kauf in Frankfurt und kurze Zeit später dann der Kurssprung in USA
Sieht aus als würde die Party nächste Woche hier weitergehen
Catalyst Pharma ( CPRX )
Marktkap : 27 Mio US$
Cash : 11,8 Mio US$
Kurs 1,78 $
Shares Out : 14,1 Mio Aktien
Insider
http://finance.yahoo.com/q/it?s=CPRX
Homepage
http://www.catalystpharma.com/about.htm
Catalyst focuses on drug to treat addicts
Catalyst Pharmaceuticals in Coral Gables is developing a drug
that could be a major help to addicts who want to quit.
BY JOHN DORSCHNER
jdorschner@MiamiHerald.com
Catalyst Pharmaceutical Partners in Coral Gables has a single drug, but it has huge potential: It suppresses dopamine levels in the brain, which could be a major factor in battling cocaine and methamphetamine addiction — and perhaps treat nicotine, alcohol, obesity and gambling problems as well.
Catalyst is a young Coral Gables drug company with a veteran industry chief executive who is betting everything on vigabatrin, an interesting drug with a long history and a problematic side effect.
"Everybody is really excited and pumped," says Chief Executive Patrick J. McEnany of the small team he has assembled.
"Drug development is a risky business. There is no doubt about it," says McEnany.
But much of the toughest work has already been done, by a federal scientist who has been studying the drug for two decades at taxpayer expense. If the drug succeeds, Catalyst could get hundreds of millions in annual revenue, but the firm will have to pay the government no more than $500,000 a year.
What's more, the Food and Drug Administration has put vigabatrin on a fast track for regulatory approval because it provides an unmet medical need for a life-threatening illness.
Vigabatrin was developed in the 1970s by an American company for the treatment of epilepsy. Under the brand name Sabril, it is now sold by a Belgium firm in more than 60 countries, but not the United States.
Antwort auf Beitrag Nr.: 37.139.610 von BrauchGeld am 10.05.09 17:37:50Ich glaube ich werde hier schnell mein Einsatz verdoppeln ...
Catalyst Pharmaceuticals Partners, Inc. (CPRX)
Rating: Market Outperform; Target Price: $9
Elemer Piros, Ph.D. – Senior Biotechnology Analyst (212.430.1754)
Panel of Experts Discuss the Promising Potential for Vigabatrin in Addiction – Transcript
Attached
• We hosted a call with four experts in the addiction therapy field to discuss positive results recently announced
from an investigator-led Phase II trial in Mexico evaluating vigabatrin for the treatment of cocaine addiction.
The experts present on the call were:
o Dr. Jonathan Brodie, professor of psychiatry at the New York University School of Medicine and coprincipal
investigator for the Phase II trial.
o Dr. Thomas R. Kosten, Professor of Psychiatry and Neuroscience at Baylor College of Medicine and
former Professor and Chief of Psychiatry at Yale University and VA Connecticut.
o Dr. Thomas F. Newton, a professor in the Department of Psychiatry and Biobehavioral Sciences.
o Dr. Eugene Somoza, is Professor of Clinical Psychiatry, Psychiatry Department, College of Medicine, at
the University of Cincinnati and Director of the Cincinnati Addiction Research Center (CinARC).
• We observed the following key points from the expert panel:
o Dr. Kosten stated that the bar to success set in this trial was very high, and it was achieved. Dr. Kosten
has previously generated data indicating that achieving abstinence for three weeks is a strong indicator
of a patient remaining abstinent for a substantially longer period of time.
o All of the doctors on the call viewed the trial results as positive, with Dr. Somoza stating that the results
“exceeded expectations”.
o It was also a general opinion that the secondary outcome measures would strengthen the results
released so far. These include drug abstinence throughout the duration of the treatment period and
reduction in cocaine use. Dr. Kosten did point out that he would expect observations of psycho-social
improvements to take longer than the three month timeframe of this trial.
o Dr. Somoza believed that the main limitation to the trial was the frequency at which urine samples were
taken (twice per week). He stated that due to the short half life (~5.5 hours) of benzoylecgonine, the
primary metabolite of cocaine assayed in abuse testing, it was possible that patients negative due to the
timing of cocaine use. Dr. Somoza did provide the caveat that any false negative would be expected to
be equally weighted between vigabatrin and placebo treated patients. Additionally it is our view that the
patient population had no incentive to “trick” investigators in this study, especially given that patients
had likely been long time abusers of cocaine.
o It was the consensus of the panel that more frequent urine sampling would be preferable in future trials
and would allow a more quantitative assessment of cocaine abstinence.
o When discussing the future for vigabatrin the doctors all expressed the opinion that vigabatrin is the
most promising developmental therapy that they have seen: Dr Newton stated that he would be
surprised if vigabatrin was not a success based on the animal and clinical data available to date. It was Dr. Somoza’s opinion that the animal data were “incredible” and he believes that the drug would likely be
active as a treatment for addiction to all stimulants.
Catalyst Pharmaceuticals Partners, Inc. (CPRX)
Rating: Market Outperform; Target Price: $9
Elemer Piros, Ph.D. – Senior Biotechnology Analyst (212.430.1754)
Panel of Experts Discuss the Promising Potential for Vigabatrin in Addiction – Transcript
Attached
• We hosted a call with four experts in the addiction therapy field to discuss positive results recently announced
from an investigator-led Phase II trial in Mexico evaluating vigabatrin for the treatment of cocaine addiction.
The experts present on the call were:
o Dr. Jonathan Brodie, professor of psychiatry at the New York University School of Medicine and coprincipal
investigator for the Phase II trial.
o Dr. Thomas R. Kosten, Professor of Psychiatry and Neuroscience at Baylor College of Medicine and
former Professor and Chief of Psychiatry at Yale University and VA Connecticut.
o Dr. Thomas F. Newton, a professor in the Department of Psychiatry and Biobehavioral Sciences.
o Dr. Eugene Somoza, is Professor of Clinical Psychiatry, Psychiatry Department, College of Medicine, at
the University of Cincinnati and Director of the Cincinnati Addiction Research Center (CinARC).
• We observed the following key points from the expert panel:
o Dr. Kosten stated that the bar to success set in this trial was very high, and it was achieved. Dr. Kosten
has previously generated data indicating that achieving abstinence for three weeks is a strong indicator
of a patient remaining abstinent for a substantially longer period of time.
o All of the doctors on the call viewed the trial results as positive, with Dr. Somoza stating that the results
“exceeded expectations”.
o It was also a general opinion that the secondary outcome measures would strengthen the results
released so far. These include drug abstinence throughout the duration of the treatment period and
reduction in cocaine use. Dr. Kosten did point out that he would expect observations of psycho-social
improvements to take longer than the three month timeframe of this trial.
o Dr. Somoza believed that the main limitation to the trial was the frequency at which urine samples were
taken (twice per week). He stated that due to the short half life (~5.5 hours) of benzoylecgonine, the
primary metabolite of cocaine assayed in abuse testing, it was possible that patients negative due to the
timing of cocaine use. Dr. Somoza did provide the caveat that any false negative would be expected to
be equally weighted between vigabatrin and placebo treated patients. Additionally it is our view that the
patient population had no incentive to “trick” investigators in this study, especially given that patients
had likely been long time abusers of cocaine.
o It was the consensus of the panel that more frequent urine sampling would be preferable in future trials
and would allow a more quantitative assessment of cocaine abstinence.
o When discussing the future for vigabatrin the doctors all expressed the opinion that vigabatrin is the
most promising developmental therapy that they have seen: Dr Newton stated that he would be
surprised if vigabatrin was not a success based on the animal and clinical data available to date. It was Dr. Somoza’s opinion that the animal data were “incredible” and he believes that the drug would likely be
active as a treatment for addiction to all stimulants.
Sind die PII Daten positiv ist das nächste Ziel ein Partner für CPP-109 zufinden was nicht schwer sein wird .....
Quartalsbericht 2009
"Catalyst made significant progress in 2008," said Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners. "During the year, we initiated two U.S. multi-center, Phase II, double-blind, placebo-controlled trials evaluating CPP-109 as a potential treatment for cocaine and methamphetamine addiction. In September we executed a successful equity financing for $4.5 million just prior to the deterioration of the capital markets and the economy. This equity raise, combined with the recently announced change in our clinical development program, provides Catalyst with sufficient working capital through 2010. Furthermore, once we report initial top-line results for our U.S. Phase II cocaine trial, our strengthened balance sheet should allow us to engage potential corporate partners and explore a variety of transactions on terms that may prove to be more favorable to our shareholders. Concurrently, we are actively pursuing government funding from agencies that operate under the National Institutes of Health umbrella to further our development plans for large-scale clinical trials using CPP-109 to treat cocaine and methamphetamine addiction, as well as pilot studies for other addictions, such as alcohol and nicotine abuse, and obsessive-compulsive disorders, including binge eating."
Quartalsbericht 2009
"Catalyst made significant progress in 2008," said Patrick J. McEnany, Chief Executive Officer of Catalyst Pharmaceutical Partners. "During the year, we initiated two U.S. multi-center, Phase II, double-blind, placebo-controlled trials evaluating CPP-109 as a potential treatment for cocaine and methamphetamine addiction. In September we executed a successful equity financing for $4.5 million just prior to the deterioration of the capital markets and the economy. This equity raise, combined with the recently announced change in our clinical development program, provides Catalyst with sufficient working capital through 2010. Furthermore, once we report initial top-line results for our U.S. Phase II cocaine trial, our strengthened balance sheet should allow us to engage potential corporate partners and explore a variety of transactions on terms that may prove to be more favorable to our shareholders. Concurrently, we are actively pursuing government funding from agencies that operate under the National Institutes of Health umbrella to further our development plans for large-scale clinical trials using CPP-109 to treat cocaine and methamphetamine addiction, as well as pilot studies for other addictions, such as alcohol and nicotine abuse, and obsessive-compulsive disorders, including binge eating."
Nachbörslich gings noch rauf bis 2,22 $ ( 1,63€ ) ..Verdoppelt sich der Kurs nächste Woche verkaufe ich sofort hab nämlich noch eine Aktie im Visier mit der man leicht geld verdienen kann .
Thomson Scientific veröffentlicht seine dritte vierteljährliche Ausgabe von Ones to Watch zur Bewertung der vielversprechendsten Arzneimittel in der pharmazeutischen Pipeline
Welches sind die Ones-to-Watch in diesem Quartal?
Nachstehend die Top fünf Arzneimittel in jeder Kategorie der Phasenwechsel:
Die fünf vielversprechendsten Arzneimittel für Phase-III-Studien
-- Bevasiranib sodium, (Wet AMD), Opko
-- Rekombinante aktive Glucocerebrosidase, (Morbus Gaucher), Protalix
-- Odanacatib, (Osteoporose), Merck & Co
-- Laquinimod, (multiple Sklerose), Active Biotech/Teva
-- Elesclomol, (solide Tumoren), Synta
Die fünf vielversprechendsten Arzneimittel für Phase-II-Studien
-- CPP-109, (Kokain- und Methamphetaminabhängigkeit), Catalyst
Pharmaceuticals
-- Intranasale Insulinrezeptur, (Diabetes), Nastech
-- LCP-AtorFen, (Cholesterol), Life Cycle
-- EC-145, (Eierstock- und Lungenkrebs), Endocyte
-- TG-100801, (AMD, diabetische makulare Ödeme, diabetische
Retinopathie), TargeGen
Die fünf vielversprechendsten Arzneimittel für Phase-I-Studien
-- Affitope AD-01, (Alzheimersche Krankheit), AFFiRiS
-- MEM-63908, (Alzheimersche Krankheit, Erkrankungen des ZNS),
Memory/Roche
-- TC-5619, (Schizophrenie, Depression), Targacept
-- RDEA-806, (HIV-Infektion), Ardea Biosciences
-- APD-791, (arterielle Thrombose), Arena Pharmaceuticals
Welches sind die Ones-to-Watch in diesem Quartal?
Nachstehend die Top fünf Arzneimittel in jeder Kategorie der Phasenwechsel:
Die fünf vielversprechendsten Arzneimittel für Phase-III-Studien
-- Bevasiranib sodium, (Wet AMD), Opko
-- Rekombinante aktive Glucocerebrosidase, (Morbus Gaucher), Protalix
-- Odanacatib, (Osteoporose), Merck & Co
-- Laquinimod, (multiple Sklerose), Active Biotech/Teva
-- Elesclomol, (solide Tumoren), Synta
Die fünf vielversprechendsten Arzneimittel für Phase-II-Studien
-- CPP-109, (Kokain- und Methamphetaminabhängigkeit), Catalyst
Pharmaceuticals
-- Intranasale Insulinrezeptur, (Diabetes), Nastech
-- LCP-AtorFen, (Cholesterol), Life Cycle
-- EC-145, (Eierstock- und Lungenkrebs), Endocyte
-- TG-100801, (AMD, diabetische makulare Ödeme, diabetische
Retinopathie), TargeGen
Die fünf vielversprechendsten Arzneimittel für Phase-I-Studien
-- Affitope AD-01, (Alzheimersche Krankheit), AFFiRiS
-- MEM-63908, (Alzheimersche Krankheit, Erkrankungen des ZNS),
Memory/Roche
-- TC-5619, (Schizophrenie, Depression), Targacept
-- RDEA-806, (HIV-Infektion), Ardea Biosciences
-- APD-791, (arterielle Thrombose), Arena Pharmaceuticals
Viel Glück. Das geht aber auch schneller mit dem verdoppeln, ich würde auf Events setzen die nicht soo fern in der Zukunft liegen
Antwort auf Beitrag Nr.: 37.140.273 von [KERN]Codex am 10.05.09 20:43:55Viel Glück. Das geht aber auch schneller mit dem verdoppeln, ich würde auf Events setzen die nicht soo fern in der Zukunft liegen
Danke ! Maximal 6 Wochen muss man warten das ist doch keine lange Zeit außerdem scheint jetzt die Aktie zu starten ..
Du übersiehst das Potential von CPP-109 wenn die Daten positiv sind wird hier die Post abgehen .....Ich sage nur Blockbuster
Danke ! Maximal 6 Wochen muss man warten das ist doch keine lange Zeit außerdem scheint jetzt die Aktie zu starten ..
Du übersiehst das Potential von CPP-109 wenn die Daten positiv sind wird hier die Post abgehen .....Ich sage nur Blockbuster
Ich hoffe, Du setzt da nicht auf einen Trugschluss: - gibt es keine Kokainabhängigen mehr, gäbe es auch keine korrupten Banker mehr...
40% aufwärts so leicht verdient man geld wohohohoho
http://finance.yahoo.com/q?s=cprx
http://finance.yahoo.com/q?s=cprx
Bin mal dabei
Ziel 2 €
Ziel 2 €
Antwort auf Beitrag Nr.: 37.382.588 von lassmichdoch am 12.06.09 16:50:51Ein glück das ich die Aktie nach dem anstieg verkauft habe !
Antwort auf Beitrag Nr.: 37.382.679 von BrauchGeld am 12.06.09 16:59:14Ich bin zu 0,60 Dollar rein vor paar Tagen
Denke hier wird es noch mächtig knallen
Denke hier wird es noch mächtig knallen
bin seit juli mit 0,30 EUR drinn.
reiner zock, .... wir warten auf den knall.
mfg zeitnehmer
reiner zock, .... wir warten auf den knall.
mfg zeitnehmer
Es bleibt spannend !
Zeitnehmer
Zeitnehmer
Schöner Umsatz am Freitag in den USA, über 430 K.
Die Aktie ist zwar nur gering gestiegen, aber es haben sich einige Positioniert.
mfg zeitnehmer
Die Aktie ist zwar nur gering gestiegen, aber es haben sich einige Positioniert.
mfg zeitnehmer
Wieder gute Umsätze heute.
Eine gute Nachricht, dann geht es abbbbbbb.
zeitnehmer
Eine gute Nachricht, dann geht es abbbbbbb.
zeitnehmer
Guter Umsatz für Catalyst.
Schöner Kurszuwachs, scheint endlich aufwärts zu gehen.
mfg zeitnehmer
Schöner Kurszuwachs, scheint endlich aufwärts zu gehen.
mfg zeitnehmer
So, bin am 23. 02 mit + 75% raus.
Beobachte aber diesen Wert weiter um eventuell wieder für einen Zock einzusteigen.
mfg zeitnehmer
Beobachte aber diesen Wert weiter um eventuell wieder für einen Zock einzusteigen.
mfg zeitnehmer
Beitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
-0,14 | |
-0,12 | |
+0,80 | |
-0,11 | |
+0,09 | |
-0,41 | |
-0,87 | |
+0,88 | |
-1,33 | |
-3,26 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
116 | ||
65 | ||
45 | ||
44 | ||
40 | ||
38 | ||
37 | ||
37 | ||
34 | ||
34 |
13:03 Uhr · globenewswire · Catalyst Pharmaceuticals |
27.03.24 · globenewswire · Catalyst Pharmaceuticals |
13.03.24 · globenewswire · Catalyst Pharmaceuticals |
05.03.24 · globenewswire · Catalyst Pharmaceuticals |
29.02.24 · globenewswire · Catalyst Pharmaceuticals |
27.02.24 · wO Chartvergleich · Danieli & C.Officine Meccaniche |
27.02.24 · globenewswire · Catalyst Pharmaceuticals |
21.02.24 · globenewswire · Catalyst Pharmaceuticals |
14.02.24 · globenewswire · Catalyst Pharmaceuticals |
22.01.24 · wO Chartvergleich · Archer Daniels Midland Company |